Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis.
Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis.
复制标题
DOI：
10.1038/s41598-020-73918-z
复制
发表时间：
2020-10-08
影响因子：
4.6
通讯作者：
Okamoto Y
中科院分区：
文献类型：
--
作者：
Erabi H;Okada G;Shibasaki C;Setoyama D;Kang D;Takamura M;Yoshino A;Fuchikami M;Kurata A;Kato TA;Yamawaki S;Okamoto Y
由于在早期阶段的最佳治疗导致症状的缓解和功能的恢复，因此需要导致早期诊断和预测治疗反应的推定的生物标志物。本研究旨在使用代谢组学方法提取参与重度抑郁症（MDD）诊断和预测艾司西酞普兰治疗反应的代谢物。我们比较了MDD患者（n = 88）与健康参与者（n = 88）的血浆代谢物，发现20种代谢物的浓度存在显著差异。我们测量了62例患者的汉密尔顿抑郁评定量表（HRSD），这些患者在治疗前后完成了大约6周的艾司西酞普兰治疗，发现犬尿烯酸和犬尿氨酸与HRSD降低显著负相关。在重叠生物标志物的73种代谢物中，仅检测到一种代谢物犬尿烯酸。犬尿烯酸在MDD中较低，较低的水平表明对艾司西酞普兰的治疗反应更好。犬尿氨酸是犬尿氨酸途径中的代谢产物，已被广泛接受为MDD的主要机制。有助于诊断和预测治疗反应的重叠生物标志物可能有助于改善疾病分类，并减少MDD患者接受效果较差的治疗。
Since optimal treatment at an early stage leads to remission of symptoms and recovery of function, putative biomarkers leading to early diagnosis and prediction of therapeutic responses are desired. The current study aimed to use a metabolomic approach to extract metabolites involved in both the diagnosis of major depressive disorder (MDD) and the prediction of therapeutic response for escitalopram. We compared plasma metabolites of MDD patients (n = 88) with those in healthy participants (n = 88) and found significant differences in the concentrations of 20 metabolites. We measured the Hamilton Rating Scale for Depression (HRSD) on 62 patients who completed approximately six-week treatment with escitalopram before and after treatment and found that kynurenic acid and kynurenine were significantly and negatively associated with HRSD reduction. Only one metabolite, kynurenic acid, was detected among 73 metabolites for overlapped biomarkers. Kynurenic acid was lower in MDD, and lower levels showed a better therapeutic response to escitalopram. Kynurenic acid is a metabolite in the kynurenine pathway that has been widely accepted as being a major mechanism in MDD. Overlapping biomarkers that facilitate diagnosis and prediction of the treatment response may help to improve disease classification and reduce the exposure of patients to less effective treatments in MDD.
登录
查看更多内容
影响因子：
6.8
作者：
Pan JX;Xia JJ;Deng FL;Liang WW;Wu J;Yin BM;Dong MX;Chen JJ;Ye F;Wang HY;Zheng P;Xie P
通讯作者：
Xie P
影响因子：
4.7
作者：
Chiarugi, A;Meli, E;Moroni, F
通讯作者：
Moroni, F
影响因子：
4
作者：
Paige, Lisa A.;Mitchell, Matthew W.;Steffens, David C.
通讯作者：
Steffens, David C.
影响因子：
3.9
作者：
BENDER, DA;MCCREANOR, GM
通讯作者：
MCCREANOR, GM
影响因子：
6.6
作者：
Gadad BS;Jha MK;Czysz A;Furman JL;Mayes TL;Emslie MP;Trivedi MH
通讯作者：
Trivedi MH